Source: Annual Congress 2008 - Severe asthma: a heterogeneous clinical entity
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Pinot, A. Nieves, A. M. Lorec, K. Botturi, A. Cavailles, D. Breen, D. Vervloet, A. Magnan (Marseille, France). A treatment regime based on induced sputum eosinophilia does not result in a reduction in exacerbations in refractory severe asthmatics. Eur Respir J 2008; 32: Suppl. 52, 1367

Member's Comments

No comment yet.

Related content which might interest you: The clinical, spirometric and cytological profiles of exacerbations in poorly controlled severe persistent asthmatics Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Long-term treatment with low-dose azithromycin reduces cough, sputum production and exacerbations in patients with idiopathic diffuse bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 707s Year: 2004 Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations Source: Eur Respir J 2006; 27: 483-494 Year: 2006 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Cellular inflammatory pattern in induced sputum among patients with stable moderate or severe asthma Source: Annual Congress 2010 - Biomarkers and Diagnosis of asthma and allergic respiratory diseases Year: 2010 Induced sputum in children with intermitent and persistent asthma: the effect to treatment Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma Year: 2007 Longitudinal variability of pulmonary function and sputum eosinophilia in severe refractory asthmatics Source: Eur Respir J 2003; 22: Suppl. 45, 479s Year: 2003 Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 The effect of montelukast on eosinophil apoptosis: Induced sputum findings of patients with mild persistant asthma Source: Eur Respir J 2003; 22: Suppl. 45, 101s Year: 2003 The association between airway and systemic eosinophilia and symptoms and exacerbations differ between asthma and COPD patients Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling Year: 2020 Induced sputum in children with mild-moderate persistent asthma: the effect of inhaled corticosteroid treatment Source: Annual Congress 2008 - Assessment of inflammation, hyperresponsiveness and response to exercise in asthmatic children Year: 2008 Airway eosinophilia is not related to clinical and functional findings in a large group of severe refractory asthmatics Source: Annual Congress 2006 - Monitoring airway inflammation – exhaled markers vs induced sputum Year: 2006 Follow-up of sputum eosinophils and cytokines during and out of exacerbations in severe refractory asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 594s Year: 2004 Heterogeneous response of airway eosinophilia to biologics in severe asthma patients Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Persistent sputum eosinophilia in patients with difficult-to-treat asthma Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up Year: 2010 Predictors of sputum eosinophilia in severe asthma Source: Virtual Congress 2020 – Clinical parameters in severe asthma Year: 2020 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Sputum induction in severe exacerbations of asthma: safety of a modified method Source: Eur Respir J 2011; 38: 979-980 Year: 2011